Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BMP1 | P13497 | 10/20 | 0.56 |
| ▸ | TAS2R14 | Q9NYV8 | 4/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | PGR | P06401 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.46 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7001435 | 0.88 | BMP1 (0.67) | BMP1TAS2R14ALDH1A1TP53 | |
| SCHEMBL6772107 | 0.87 | ALDH1A1 (0.47) | BMP1ALDH1A1GAALMNAMAPT | |
| SCHEMBL7112761 | 0.83 | BMP1 (0.72) | BMP1TAS2R14ALDH1A1MAPTKMT2A | |
| SCHEMBL7003476 | 0.82 | BMP1 (0.69) | BMP1TAS2R14ALDH1A1 | |
| SCHEMBL7004788 | 0.78 | BMP1 (0.66) | BMP1TAS2R14ALDH1A1KMT2A | |
| SCHEMBL6772731 | 0.78 | TDP1 (0.51) | BMP1ALDH1A1GAALMNA | |
| SCHEMBL7093324 | 0.78 | TP53 (0.65) | BMP1TAS2R14ALDH1A1GAAMEN1 | |
| SCHEMBL7886751 | 0.77 | BMP1 (0.58) | BMP1TAS2R14ALDH1A1GAAMEN1 | |
| Acrylic Acid Ethyl Ester SCHEMBL7145276 | 0.76 | BMP1 (0.61) | BMP1TAS2R14ALDH1A1 | |
| SCHEMBL6999599 | 0.76 | BMP1 (0.61) | BMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6833366-B1 | Dihydrostilbene alkanoic acid derivatives | PHARMACIA CORPORATION | 2004-12-21 | — | — | US | disclosed |
| US-6720315-B2 | FOR INHIBITING BONE RESORPTION, PERIODONTAL DISEASE, OSTEOPOROSIS, HUMORAL HYPERCALCEMIA OF MALIGNANCY, PAGET'S DISEASE, TUMOR METASTASIS, SOLID TUMOR GROWTH, ANGIOGENESIS, MACULAR DEGENERATION AND DIABETIC RETINOPATHY RETINOPATHY | PHARMACIA CORPORATION | 2004-04-13 | — | — | US | disclosed |
| EP-1289959-A1 | DIHYDROSTILBENE ALKANOIC ACID DERIVATIVES USEFUL AS VITRONECTIN ANTAGONISTS | Pharmacia Corporation (US) | 2003-03-12 | — | — | EP | disclosed |
| US-20020099209-A1 | Dihydrostilbene alkanoic acid derivatives | PHARMACIA CORPORATION | 2002-07-25 | — | — | US | disclosed |
| WO-2001096310-A1 | DIHYDROSTILBENE ALKANOIC ACID DERIVATIVES USEFUL AS VITRONECTIN ANTAGONISTS | PHARMACIA CORPORATION (US) | 2001-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020099209-A1 | Dihydrostilbene alkanoic acid derivatives | ITGA5, ITGB5, ITGB1 | BMP1 688/4885TAS2R14 1718/4885ALDH1A1 94/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.